Enclomiphene
The SERM That Raises Endogenous Testosterone While Preserving Fertility
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved for hypogonadism (use is off-label; the trans-isomer of clomiphene)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about enclomiphene in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator that blocks estrogen feedback at the hypothalamus and pituitary, increasing LH and FSH and thereby stimulating endogenous testosterone production. Because it works upstream, it preserves spermatogenesis and testicular size, its main advantage over exogenous TRT. It is marketed prominently by Maximus Tribe and Hims, though it is not FDA-approved for hypogonadism.
Raise your own testosterone without shutting the system down, the telehealth alternative to direct TRT.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Enclomiphene antagonizes estrogen receptors at the hypothalamus and pituitary, removing estrogen's negative feedback. The pituitary responds with increased LH and FSH secretion, stimulating Leydig cells to produce more testosterone and supporting spermatogenesis. Unlike exogenous testosterone, which suppresses the axis, enclomiphene drives it, so endogenous production and fertility are maintained. It works only in men whose testes and pituitary can still respond (secondary hypogonadism).
Why brands call it 'natural optimization'
Maximus Tribe markets enclomiphene as 'natural testosterone optimization,' distinct from direct TRT, and Hims offers it as a primary testosterone product. The mechanism does stimulate the body's own production and spares fertility, a real pharmacologic difference. But enclomiphene is a prescription SERM used off-label, not a supplement, and 'natural' refers to the endogenous production pathway, not to the drug being natural. Long-term outcome data are more limited than for established TRT.
Safety in detail
This is a prescription drug used off-label and requires physician evaluation and monitoring. Changes to hormones, sexual function, or sexual health warrant evaluation by a qualified healthcare provider.
What it does to fertility
Enclomiphene's defining advantage is that, by raising LH and FSH rather than suppressing them, it preserves and can improve spermatogenesis and testicular volume, making it a preferred option for men who want higher testosterone while maintaining fertility, in contrast to exogenous TRT.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total and free testosterone
- LH and FSH (to confirm axis response)
- Estradiol (SERMs alter estrogen signaling)
- Semen analysis if fertility is a goal
What people get wrong
Often saidEnclomiphene is a natural supplement
ActuallyIt is a prescription selective estrogen receptor modulator used off-label, marketed as 'natural optimization' because it stimulates endogenous testosterone, but it is a drug, not a supplement.
Often saidIt works for everyone with low testosterone
ActuallyIt requires an intact, responsive HPG axis (secondary hypogonadism). In primary testicular failure, where the testes cannot respond, it will not raise testosterone.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Class
- SERM (trans-clomiphene)
- Mechanism
- Blocks estrogen feedback, raises LH/FSH
- Key advantage
- Preserves fertility
- FDA status
- Not approved for hypogonadism (off-label)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Enclomiphene. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Enclomiphene citrate phase trials (Wiehle et al.)2014 onward
Enclomiphene raised total testosterone into the normal range while maintaining or increasing LH, FSH, and sperm counts, contrasting with the suppression seen on gel TRT, establishing its fertility-sparing profile